BIOA and BIOA B Related Headlines
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- BioArctic publishes the Annual Report and Sustainability Report for 2025
BIOA and BIOA B Related Press Releases
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- Bulletin from the Annual General Meeting in BioArctic AB (publ)
- BioArctic publishes the Annual Report and Sustainability Report for 2025
